This handout is for recurrent dvt on therapeutic anticoagulation (treatment failure). Your care team identified this based on: new unilateral leg swelling/pain in patient on therapeutic-dose ac ≥4 weeks → confirm dvt and classify as breakthrough vte.
Other reasons your team may use this plan: compression us confirms new dvt (different segment or new thrombus extension) in patient on documented therapeutic ac; documented breakthrough vte while on therapeutic ac ≥4 weeks — treatment failure pathway initiated; root cause analysis mandatory; subtherapeutic anti-xa or inr in patient with confirmed vte on prescribed ac — adherence vs interaction vs malabsorption vs dose insufficiency differential.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| enoxaparin | 1 mg/kg SC BID; escalate to 1.5 mg/kg BID short-term for severe breakthrough; reduce to 1 mg/kg daily if CrCl <30 | SC | BID × ≥1 month then reassess | ACCP 2021 (PMID 34352295) — switch DOAC to LMWH for breakthrough VTE; LMWH has guaranteed bioavailability and dose-response; LITE-2 (Lee 2024) supports increased-dose LMWH for breakthrough; ASH 2020 (PMID 33007077) |
| dalteparin | 200 IU/kg SC daily × 1 month → 150 IU/kg SC daily | SC | daily × ≥1 month | CLOT (Lee NEJM 2003 PMID 12853587) — dalteparin first-line for cancer-VTE; if breakthrough is cancer-driven, switch to dalteparin per ISTH 2022 |
| warfarin | 5 mg daily; INR target 2-3 (target 3-4 if recurrent on therapeutic warfarin) | PO | daily | TRAPS (Pengo Blood 2018 PMID 30196097) — rivaroxaban inferior to warfarin in triple-positive APS (early stop for excess thromboembolism); RAPS (Cohen Lancet Haematol 2016 PMID 27932287) — rivaroxaban inferior in APS; ISTH 2024 — warfarin INR 2-3 mandatory for APS-VTE |
| apixaban | 10 mg BID × 7 d → 5 mg BID; consider 10 mg BID extended if breakthrough on standard dose without APS | PO | BID | AMPLIFY (Agnelli NEJM 2013 PMID 23808982); switch from warfarin to DOAC if subtherapeutic INR was the cause; avoid if APS |
| rivaroxaban | 15 mg BID × 21 d → 20 mg daily with food | PO | BID then daily | EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814); avoid if APS — TRAPS / RAPS data |
| heparin | 80 U/kg bolus + 18 U/kg/h infusion targeting aPTT 1.5-2.5× | IV | continuous | Reversibility with protamine; rapid onset; preferred in hemodynamic instability or peri-procedural (ACCP 2021) |
Plan: Recurrent DVT on therapeutic AC — switch class, escalate intensity, or APS-mandated warfarin (ACCP 2021 / ISTH 2024)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Indefinite AC after second VTE event regardless of provoking factor (ACCP 2021); APS triple-positive lifelong warfarin; cancer-driven recurrence → switch to cancer-VTE pathway with cancer-active indefinite AC; share decision with patient on bleed-vs-recurrence tradeoff
Guideline: ACCP/CHEST 2021 Antithrombotic + ASH 2020 VTE Treatment + ISTH 2024 antiphospholipid + TRAPS / RAPS for APS-VTE